These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

524 related articles for article (PubMed ID: 32351498)

  • 1. CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers.
    Harvey JB; Phan LH; Villarreal OE; Bowser JL
    Front Immunol; 2020; 11():508. PubMed ID: 32351498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer.
    Allard B; Turcotte M; Stagg J
    Expert Opin Ther Targets; 2014 Aug; 18(8):863-81. PubMed ID: 24798880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Immunometabolism Mediated by CD73 Pathway in
    Passarelli A; Aieta M; Sgambato A; Gridelli C
    Front Immunol; 2020; 11():1479. PubMed ID: 32760402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the Immunomodulatory CD73/Adenosine System to Improve the Therapeutic Gain of Radiotherapy.
    de Leve S; Wirsdörfer F; Jendrossek V
    Front Immunol; 2019; 10():698. PubMed ID: 31024543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade.
    Yang R; Elsaadi S; Misund K; Abdollahi P; Vandsemb EN; Moen SH; Kusnierczyk A; Slupphaug G; Standal T; Waage A; Slørdahl TS; Rø TB; Rustad E; Sundan A; Hay C; Cooper Z; Schuller AG; Woessner R; Borodovsky A; Menu E; Børset M; Sponaas AM
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32409420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The metabolic milieu in melanoma: Role of immune suppression by CD73/adenosine.
    Passarelli A; Tucci M; Mannavola F; Felici C; Silvestris F
    Tumour Biol; 2019 Apr; 42(4):1010428319837138. PubMed ID: 30957676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD73 as a potential opportunity for cancer immunotherapy.
    Ghalamfarsa G; Kazemi MH; Raoofi Mohseni S; Masjedi A; Hojjat-Farsangi M; Azizi G; Yousefi M; Jadidi-Niaragh F
    Expert Opin Ther Targets; 2019 Feb; 23(2):127-142. PubMed ID: 30556751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors.
    Beavis PA; Divisekera U; Paget C; Chow MT; John LB; Devaud C; Dwyer K; Stagg J; Smyth MJ; Darcy PK
    Proc Natl Acad Sci U S A; 2013 Sep; 110(36):14711-6. PubMed ID: 23964122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-cell RNA sequencing reveals distinct cellular factors for response to immunotherapy targeting CD73 and PD-1 in colorectal cancer.
    Kim M; Min YK; Jang J; Park H; Lee S; Lee CH
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34253638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment.
    Mediavilla-Varela M; Castro J; Chiappori A; Noyes D; Hernandez DC; Allard B; Stagg J; Antonia SJ
    Neoplasia; 2017 Jul; 19(7):530-536. PubMed ID: 28582704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting adenosine and regulatory T cells in cancer immunotherapy.
    Churov A; Zhulai G
    Hum Immunol; 2021 Apr; 82(4):270-278. PubMed ID: 33610376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Prognostic Role of CD73/A2AR Expression and Tumor Immune Response in Periampullary Carcinoma Subtypes.
    Sweed D; Taha M; Abd Elhamed S; El Dein Mohamed AS
    Asian Pac J Cancer Prev; 2022 Apr; 23(4):1239-1246. PubMed ID: 35485681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD73 on cancer-associated fibroblasts enhanced by the A
    Yu M; Guo G; Huang L; Deng L; Chang CS; Achyut BR; Canning M; Xu N; Arbab AS; Bollag RJ; Rodriguez PC; Mellor AL; Shi H; Munn DH; Cui Y
    Nat Commun; 2020 Jan; 11(1):515. PubMed ID: 31980601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting adenosine for cancer immunotherapy.
    Leone RD; Emens LA
    J Immunother Cancer; 2018 Jun; 6(1):57. PubMed ID: 29914571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses.
    Young A; Ngiow SF; Barkauskas DS; Sult E; Hay C; Blake SJ; Huang Q; Liu J; Takeda K; Teng MWL; Sachsenmeier K; Smyth MJ
    Cancer Cell; 2016 Sep; 30(3):391-403. PubMed ID: 27622332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockade of adenosine A2A receptor enhances CD8
    Ma SR; Deng WW; Liu JF; Mao L; Yu GT; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
    Mol Cancer; 2017 Jun; 16(1):99. PubMed ID: 28592285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extracellular purine metabolism and signaling of CD73-derived adenosine in murine Treg and Teff cells.
    Romio M; Reinbeck B; Bongardt S; Hüls S; Burghoff S; Schrader J
    Am J Physiol Cell Physiol; 2011 Aug; 301(2):C530-9. PubMed ID: 21593451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD73 on T Cells Orchestrates Cardiac Wound Healing After Myocardial Infarction by Purinergic Metabolic Reprogramming.
    Borg N; Alter C; Görldt N; Jacoby C; Ding Z; Steckel B; Quast C; Bönner F; Friebe D; Temme S; Flögel U; Schrader J
    Circulation; 2017 Jul; 136(3):297-313. PubMed ID: 28432149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenosine signaling: Next checkpoint for gastric cancer immunotherapy?
    Shi L; Yang L; Wu Z; Xu W; Song J; Guan W
    Int Immunopharmacol; 2018 Oct; 63():58-65. PubMed ID: 30075429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD73-derived adenosine controls inflammation and neurodegeneration by modulating dopamine signalling.
    Meng F; Guo Z; Hu Y; Mai W; Zhang Z; Zhang B; Ge Q; Lou H; Guo F; Chen J; Duan S; Gao Z
    Brain; 2019 Mar; 142(3):700-718. PubMed ID: 30689733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.